hat
NCT03061201. Yon Faz 1/2, Louvri-etikèt, Adaptatif, etid Dòz-K ap evalye Sekirite Sosyal la ak Tolerabilite nan SB-525 (Recombinant AAV2 / 6 Imèn Faktè Terapi jèn 8 moun) nan granmoun pou Timoun ki gen emofil grav .. https://clinicaltrials.gov/ct2/show/NCT03061201
eng
NCT03061201. A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A. https://clinicaltrials.gov/ct2/show/NCT03061201